Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19655025 | 0.75 | DYRK1A (0.35) | — | |
| SCHEMBL19499607 | 0.75 | DYRK1A (0.35) | — | |
| SCHEMBL24975332 | 0.75 | P2RX7 (0.30) | P2RX7 | |
| SCHEMBL8593025 | 0.71 | — | — | |
| SCHEMBL8591521 | 0.71 | — | — | |
| SCHEMBL20468260 | 0.70 | P2RX7 (0.39) | CYP1A2CYP2C19P2RX7 | |
| SCHEMBL20468185 | 0.70 | HCAR2 (0.33) | — | |
| SCHEMBL12565976 | 0.67 | — | — | |
| SCHEMBL12465346 | 0.62 | DYRK1A (0.48) | — | |
| SCHEMBL12354209 | 0.62 | DYRK1A (0.48) | CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227470-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | VANDERBILT UNIVERSITY | 2023-07-20 | — | — | US | disclosed |
| US-20230227470-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | VANDERBILT UNIVERSITY | 2023-07-20 | — | — | US | disclosed |
| US-20180221334-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS | GILEAD SCIENCES, INC. | 2018-08-09 | — | — | US | disclosed |
| US-9895347-B2 | Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis | GALAPAGOS NV (BE) | 2018-02-20 | — | — | US | disclosed |
| US-9895347-B2 | Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis | GALAPAGOS NV (BE) | 2018-02-20 | — | — | US | disclosed |
| US-20160317493-A1 | Novel Compounds and Pharmaceutical Compositions Thereof for the Treatment of Cystic Fibrosis | GILEAD SCIENCES, INC. | 2016-11-03 | — | — | US | disclosed |
| US-9351955-B2 | Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis | GALAPAGOS NV (BE) | 2016-05-31 | — | — | US | disclosed |
| US-20160022633-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS | GILEAD SCIENCES, INC. | 2016-01-28 | — | — | US | disclosed |
| US-9133210-B2 | Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis | GALAPAGOS NV (BE) | 2015-09-15 | — | — | US | disclosed |
| US-20150045327-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS | GILEAD SCIENCES, INC. | 2015-02-12 | — | — | US | disclosed |
| US-8575197-B2 | Pyrolinone derivative and pharmaceutical composition comprising the same | SHIONOGI & CO., LTD. (JP) | 2013-11-05 | — | — | US | disclosed |
| US-8497263-B2 | Pyrrolinone derivative and pharmaceutical composition comprising the same | SHIONOGI & CO., LTD. (JP) | 2013-07-30 | — | — | US | disclosed |
| US-8101644-B2 | Pyrrolinone derivative and pharmaceutical composition comprising the same | SHIONOGI & CO., LTD. (JP) | 2012-01-24 | — | — | US | disclosed |
| US-20120010199-A1 | NOVEL PYRROLINONE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | KAI HIROYUKI (JP) | 2012-01-12 | — | — | US | disclosed |
| US-20110183939-A1 | NOVEL PYROLINONE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | SHIONOGI & CO., LTD. (JP) | 2011-07-28 | — | — | US | disclosed |
| US-20100210632-A1 | NOVEL PYRROLINONE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | SHIONOGI & CO., LTD. (JP) | 2010-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183939-A1 | NOVEL PYROLINONE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | P2RX3, P2RX7, P2RX2 | CYP1A2 338/4885CYP2C19 137/4885P2RX7 2/4885 |
| US-20120010199-A1 | NOVEL PYRROLINONE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | P2RX3, P2RX2, P2RX1 | CYP1A2 1012/4885CYP2C19 812/4885P2RX7 4/4885 |
| US-20100210632-A1 | NOVEL PYRROLINONE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | P2RX3, P2RX2, P2RX1 | CYP1A2 1012/4885CYP2C19 812/4885P2RX7 4/4885 |
| US-20230227470-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | KRAS, NRAS, TP53 | CYP1A2 1616/4885CYP2C19 1386/4885P2RX7 1831/4885 |
| US-20180221334-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, ABCB11, ABCC5 | CYP1A2 1209/4885CYP2C19 1140/4885P2RX7 516/4885 |
| US-20160022633-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, ABCB11, ABCC5 | CYP1A2 1209/4885CYP2C19 1140/4885P2RX7 516/4885 |
| US-20160317493-A1 | Novel Compounds and Pharmaceutical Compositions Thereof for the Treatment of Cystic Fibrosis | CFTR, ABCB11, ABCC5 | CYP1A2 1209/4885CYP2C19 1140/4885P2RX7 516/4885 |
| US-20150045327-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, ABCB11, ABCC5 | CYP1A2 1209/4885CYP2C19 1140/4885P2RX7 516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.